ALHC shares slide as CMS downgrades H3815 star rating to 3.5
Oct 14, 2026, 4:59 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The downgrade directly reduces upside from quality bonuses and capitation-linked reimbursements while exposing ALHC to enrollment and retention headwinds; the immediate price reaction (13% decline) demonstrates market re-pricing of regulatory risk. Similar past moves in managed-care have led to short-term volatility and multiple expansion re-rating until remediation is evident.
AI summary
What happened, with direct paths to the underlying reporting
Alignment Healthcare (ALHC) tumbled after CMS lowered the California HMO contract H3815’s 2027 star rating from 4.0 to 3.5, citing performance concerns and new cut points. H3815 covers about 75% of ALHC’s membership, making the downgrade a material headwind for reimbursements and quality incentives. The sell-off underscores near-term investor risk and uncertainty around remediation timelines.
CMS cuts ALHC H3815 star rating from 4.0 to 3.5; 75% of membership affected.
ALHC stock fell 13% on Oct 9, 2026 to $7.55, hitting a 52-week low.
Downgrade tied to CMS measurement-period concerns and new cut points.
H3815 contract covers about 75% of ALHC membership, heightening revenue risk.
Impact on future reimbursements and incentives if star rating remains weak.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
